Stratos Wealth Partners LTD. increased its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 321,553 shares of the biopharmaceutical company’s stock after purchasing an additional 2,025 shares during the quarter. Bristol-Myers Squibb accounts for approximately 0.9% of Stratos Wealth Partners LTD.’s investment portfolio, making the stock its 19th largest holding. Stratos Wealth Partners LTD.’s holdings in Bristol-Myers Squibb were worth $17,917,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 17 shares during the period. Keel Point LLC lifted its holdings in Bristol-Myers Squibb by 0.3% in the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 18 shares during the period. Staley Capital Advisers Inc. lifted its holdings in Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after acquiring an additional 24 shares during the period. Shayne & CO. LLC lifted its holdings in Bristol-Myers Squibb by 0.6% in the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares during the period. Finally, Physicians Financial Services Inc. lifted its holdings in Bristol-Myers Squibb by 0.4% in the first quarter. Physicians Financial Services Inc. now owns 9,929 shares of the biopharmaceutical company’s stock valued at $540,000 after acquiring an additional 39 shares during the period. 68.87% of the stock is owned by hedge funds and other institutional investors.

Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 65.35 on Friday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $65.73. The stock has a market capitalization of $107.17 billion, a PE ratio of 23.87 and a beta of 1.19. The stock has a 50 day moving average price of $62.45 and a 200-day moving average price of $56.90.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm earned $0.69 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.39%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/10/13/stratos-wealth-partners-ltd-grows-position-in-bristol-myers-squibb-company-bmy.html.

BMY has been the subject of a number of analyst reports. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 10th. Jefferies Group LLC reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. Finally, Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 price target for the company in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $62.71.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at approximately $1,006,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.